Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 1/20 | 0.34 |
| ▸ | TK2 | O00142 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 6/20 | 0.33 |
| ▸ | CA2 | P00918 | 6/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.32 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21138004 | 1.00 | MEN1 (0.36) | MEN1GAAKMT2APTGS1PTGS2 | |
| SCHEMBL21137953 | 0.83 | PYGB (0.45) | PTGS1PTGS2TLR4PYGBSLC2A1 | |
| SCHEMBL21138039 | 0.83 | PYGB (0.45) | PTGS1PTGS2TLR4PYGBSLC2A1 | |
| SCHEMBL21138017 | 0.83 | PYGB (0.38) | KMT2ATLR4PYGB | |
| SCHEMBL21058398 | 0.83 | PYGB (0.38) | KMT2ATLR4PYGB | |
| SCHEMBL31353005 | 0.82 | TLR4 (0.44) | TLR4PYGB | |
| SCHEMBL21137910 | 0.82 | TLR4 (0.44) | TLR4PYGB | |
| SCHEMBL21137960 | 0.81 | PYGB (0.40) | PTGS1PTGS2TLR4PYGBSLC2A1 | |
| SCHEMBL21137917 | 0.81 | PYGB (0.40) | PTGS1PTGS2TLR4PYGBSLC2A1 | |
| SCHEMBL21058358 | 0.80 | TLR4 (0.42) | PTGS1PTGS2TLR4PYGBSLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2025-11-20 | — | — | US | disclosed |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2025-05-27 | — | — | US | disclosed |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2024-02-15 | — | — | US | disclosed |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| CN-115594724-A | Glucosamine derivatives for preventing or treating joint diseases | 润佳（苏州）医药科技有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-111971290-B | Glucosamine derivatives for preventing or treating joint diseases | 润佳（苏州）医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| CN-111971290-A | Glucosamine derivatives for preventing or treating joint diseases | 润佳（苏州）医药科技有限公司 | 2020-11-20 | — | — | CN | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353870-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | MEN1 2062/4885GAA 89/4885KMT2A 4171/4885 |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, GLA | MEN1 1741/4885GAA 120/4885KMT2A 4314/4885 |
| US-20240051982-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, FUT6 | MEN1 1516/4885GAA 141/4885KMT2A 4082/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | MEN1 1741/4885GAA 120/4885KMT2A 4314/4885 |
| US-12552823-B2 | Glucosamine derivatives and pharmaceutical uses thereof | SOST, FUT6, SLC5A1 | MEN1 4232/4885GAA 603/4885KMT2A 4311/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | MEN1 2062/4885GAA 89/4885KMT2A 4171/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | MEN1 2062/4885GAA 89/4885KMT2A 4171/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | MEN1 2062/4885GAA 89/4885KMT2A 4171/4885 |
| US-12312378-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, FUT6 | MEN1 1516/4885GAA 141/4885KMT2A 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.